Abstract
Sphingolipids (SLs) are essential constituents of cell membranes and important signaling molecules. Clinical studies showed, that sphingolipids, and in particular ceramides, are associated with metabolic diseases such as type 2 diabetes mellitus, hepatic steatosis, and coronary heart disease. This has been recapitulated in cell and animal models, demonstrating that increased ceramide levels promote hepatic steatosis, insulin resistance, β cell dysfunction, and apoptosis.1 In this issue, Schmidt and colleagues describe a therapeutic approach employing anti-sense oligonucleotides (ASOs) to reduce ceramide synthase 2 (CerS2) expression in mice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
